Lazertinib was exported to Janssen in 2018 worth 1.4 trillion won. Janssen is attempting to overcome existing treatments through the combination of its developed non-small cell lung cancer treatment "Amivantamab (Rybrevant)" and Lazertinib.

The MFDS approved a phase 3 clinical trial plan for "JNJ-61186372" applied by Janssen Korea on the 10th. This clinical trial is the second phase 3 combination therapy of Amivantamab-Lazertinib in Korea.

This test is a phase 3, label disclosure, and randomized clinical trial comparing platinum-based chemotherapy and combination therapy of Amivantamab and Lazertinib in clinical trial subjects with EGFR-mutagenic or metastatic non-small cell lung cancer t